 Cortexyme, Inc. Nasdaq: CRTX, a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimers and other degenerative diseases, today announced financial results for the fourth quarter and full year 2019 and provided an update on its business. 